DEF: Iterum Seeks Shareholder Approval to Avoid Delisting, Fund Operations

Iterum Therapeutics plc calls an Extraordinary General Meeting to approve critical proposals for capital raising and Nasdaq compliance, warning of potential bankruptcy if not approved.

Summary

• Shareholders are asked to approve an increase in authorized share capital from $1,800,000 to $2,300,000 by creating an additional 50,000,000 ordinary shares.
• Approval is sought for an updated authority for the board of directors to allot and issue shares, warrants, convertible instruments, and options for a five-year period.
• Shareholders are asked to grant the board authority to issue shares for cash without pre-emptive rights, also for a five-year period.
• A reverse share split (consolidation) at a ratio of 1-for-10 to 1-for-15 is proposed to regain compliance with Nasdaq's minimum $1.00 bid price rule.
• The board unanimously recommends voting FOR all four proposals.
• Failure to approve the share allotment proposals would severely restrict capital raising, materially and adversely affect operations, and likely result in bankruptcy, liquidation, or dissolution.
• Failure to approve the reverse share split proposal would likely lead to delisting from the Nasdaq Capital Market, hindering funding and potentially resulting in bankruptcy or liquidation.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the company's critical financial state, non-compliance with Nasdaq listing rules, and explicit warnings of potential bankruptcy or delisting if shareholder proposals are not approved. While the proposals aim to address these issues, they are presented as urgent survival measures rather than growth opportunities, reflecting a highly distressed situation.

Positives

• The proposed actions, if approved and successfully implemented, could enable the company to raise necessary capital to fund ORLYNVAH commercialization and maintain its Nasdaq listing.
• The board is actively addressing Nasdaq compliance issues and seeking shareholder support for critical survival measures.

Negatives

• The company is in a precarious financial position, with current cash and equivalents only sufficient to fund operations into early Q2 2026.
• The company is non-compliant with Nasdaq's minimum $1.00 bid price rule and the $35 million Market Value of Listed Securities (MVLS) requirement.
• Failure to approve the proposals carries severe risks, including bankruptcy, liquidation, dissolution, or delisting from Nasdaq.
• The previous 2024 Rights Offering was time-consuming (3.5 months) and costly (over $1.6 million in fees), highlighting past difficulties in capital raising.

Risks

• Inability to raise additional capital if Share Allotment Proposals are not approved, leading to material adverse effects on operations, financial condition, and ability to continue as a going concern, potentially resulting in bankruptcy, liquidation, dissolution, or wind-down of operations.
• Delisting from the Nasdaq Capital Market if the Reverse Share Split Proposal is not approved or if compliance with Nasdaq rules is not regained, which would hinder funding ability and potentially lead to bankruptcy, liquidation, dissolution, or wind-down of operations.
• Loss of investor confidence and decline in share price due to substantial doubt about the company's ability to continue as a going concern.
• No assurance that the Reverse Share Split will result in a permanent increase in share price or that the company will remain compliant with Nasdaq listing standards.
• Potential harm to liquidity if the Reverse Share Split is implemented, particularly if the expected increase in share price is not sustained, and increased costs for shareholders owning odd lots.
• The company is not currently eligible for an additional 180-day compliance period for the Bid Price Rule due to non-compliance with the Minimum MVLS Requirement.

Future Outlook

The company expects its current cash and cash equivalents, combined with recent at-the-market offering proceeds, to fund operations only into the beginning of Q2 2026. Future viability beyond this period is dependent on successfully raising additional capital, primarily through equity issuances, and potential sales of ORLYNVAH. The board believes the proposed share allotment and reverse share split are critical to continuing operations and achieving business objectives, including the ongoing commercialization of ORLYNVAH.

Management Comments

• "Failure to obtain approval of the Share Allotment Proposals will restrict the Company's ability to raise additional capital, and the Company's operations, financial condition and ability to continue as a going concern may be materially and adversely affected, which would likely result in a bankruptcy, liquidation, dissolution, wind-down of operations or similar proceeding or outcome in which shareholders would be unlikely to receive any meaningful distribution or return on their investment."
• "Failure to obtain approval of the Reverse Share Split Proposal likely will ultimately result in the ordinary shares of the Company being delisted from the Nasdaq Capital Market, which would hinder the Company's ability to raise necessary funding and which may materially and adversely affect the Company's ability to continue as a going concern, likely resulting in a bankruptcy, liquidation, dissolution, wind-down of operations or similar proceeding or outcome in which shareholders would be unlikely to receive any meaningful distribution or return on their investment."
• "Our board of directors unanimously recommends a vote FOR Proposal Nos. 1 through 4 as set forth in the proxy statement."
• "We have explored other sources of financing including non-dilutive funding options, but we been unable to secure such financing to date."
• "The 2024 Rights Offering was time-consuming and costly, taking approximately three and a half months to implement and with costs in excess of $1.6 million (including dealer-manager fees)."

Industry Context

The company operates in the pharmaceutical industry, specifically focusing on the commercialization of ORLYNVAH. Its need for frequent capital raises and reliance on equity financing, coupled with challenges in securing non-dilutive funding, suggests a common characteristic of early-stage or growth-phase pharmaceutical companies. The compliance issues with Nasdaq's listing rules (bid price and MVLS) are critical for maintaining visibility and access to broader capital markets, a common challenge for smaller biotech firms with fluctuating stock prices and market valuations.

Comparison to Industry Standards

• The company's need to seek shareholder approval for share issuance authorities and pre-emption rights opt-out is due to its Irish incorporation, which differs from customary U.S. capital markets practices where U.S.-incorporated companies listed on Nasdaq generally do not require such frequent approvals.
• The company notes that some proxy advisory firms used to apply UK/Ireland voting guidelines (limiting share allotment to 33% and pre-emption opt-out to 10-20% of issued capital) to Irish-incorporated U.S.-listed companies, but now recommend up to 50% for early-stage companies heavily reliant on equity financing, which Iterum believes is more appropriate for its situation.
• The company explicitly states that adhering to the stricter Irish market practice limitations would disadvantage it relative to its U.S.-incorporated, U.S.-listed peers, who are not subject to similar statutory pre-emption rights and can access capital markets more quickly.
• The 2024 Rights Offering, which was time-consuming (3.5 months) and costly (over $1.6 million), serves as an example of the competitive disadvantage faced without the proposed pre-emption rights opt-out, contrasting with the more efficient capital access typically available to U.S.-incorporated companies.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Face significant dilution if capital raise proposals are approved and implemented. Will experience a reduction in the number of shares held but a proportionate increase in nominal value per share if the reverse split occurs. Risk of substantial loss of investment if proposals fail and the company faces bankruptcy or delisting.
• **Employees**: Company's ability to continue as a going concern directly impacts job security. Equity incentives (options, RSUs) will be adjusted proportionately if a reverse split occurs.
• **Customers (ORLYNVAH users)**: Continued commercialization of ORLYNVAH depends on successful capital raising, impacting product availability and support.
• **Creditors**: Risk of non-payment if the company enters bankruptcy or liquidation due to failure of proposals.
• **Nasdaq**: The company's compliance with listing rules is at stake, impacting its status on the exchange.

Next Steps

• Shareholders to vote on proposals at the Extraordinary General Meeting on February 18, 2026.
• If Share Allotment Proposals are approved, the company plans to undertake an equity financing in the near term.
• If Reverse Share Split Proposal is approved and deemed necessary by the board, the company will publicly announce its intention to proceed, specifying the effective time and date and consolidation ratio.
• If the company does not regain Bid Price Rule compliance by February 23, 2026, it will receive a delisting letter and plans to file an appeal while completing the Reverse Share Split process.
• The company will need to raise additional capital throughout 2026 to fund operations and ORLYNVAH commercialization.

Key Dates

Recommendation

The filing presents a dire situation for Iterum Therapeutics, indicating a high probability of bankruptcy, liquidation, or delisting from Nasdaq if the proposed resolutions are not approved. The company is already non-compliant with multiple Nasdaq listing rules (bid price and MVLS) and has a very short cash runway, expecting funds to last only into early Q2 2026. While the proposals are necessary for survival, their approval does not guarantee long-term viability or a sustained recovery in share price. The explicit warnings of 'unlikely to receive any meaningful distribution or return on their investment' in case of failure, coupled with the company's inability to secure non-dilutive funding and the costly nature of previous capital raises, suggest a highly distressed asset. A seasoned investor would likely view this as a 'strong sell' to minimize further losses, as the fundamental business challenges and financial instability appear overwhelming, even if these emergency measures are passed.

Keywords

Iterum Therapeutics, SEC Filing, Proxy Statement, Extraordinary General Meeting, Share Capital Increase, Reverse Stock Split, Nasdaq Delisting, Capital Raise, ORLYNVAH, Going Concern, Biotechnology, Pharmaceuticals, Corporate Governance, Shareholder Vote